Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Rui Chen, Ph.D
Peking Union Medical College Hospital
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
- Shenzhen Protgen Co., Ltd.
Shenzhen, Guangdong, China
- Shenzhen Third People'S Hospital
Shenzhen, Guangdong, China
- Hebei Petro China Central Hospital
Shijiazhuang, Hebei, China
- the First Hospital of Changsha
Changsha, Hunan, China
- Yiyang Central Hospital
Yiyang, Hunan, China
- Pingxiang People'S Hospital
Pingxiang, Jiangxi, China
- Yichun People'S Hospital
Yichun, Jiangxi, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 14 Oct 2021
- Primary completion
- 16 May 2022
- Completion
- 16 May 2022
- Last update posted
- 11 Mar 2026
- Registered enrollment
- 36
- Registry id
- NCT05249374
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.